The GLP-1 battle heats up with new preliminary knowledge from Eli Lilly displaying that sufferers utilizing its weight reduction drug Zepbound misplaced extra weight on common in 72 weeks — 20.2% of their physique weight — than these on Novo Nordisk’s Wegovy, who misplaced solely 13.7%.
Novo’s Wegovy presently has a higher market share than Eli Lilly’s Zepbound, but when this new knowledge holds up payers could tip the steadiness in favor of the Indianapolis-based pharma firm sooner or later.
Learn the complete article right here.
